Medical/Pharmaceuticals

MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia

SINGAPORE, June 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ("Asia PGI"), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently...

2025-06-11 14:36 2292

Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review

HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine,Global Banking and Finance Review, that it has received three awards: "ESG & Sustainability Awards – Best Sustainable Development Company As...

2025-06-11 14:04 4132

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱® ) was...

2025-06-11 11:34 2325

Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...

2025-06-10 23:52 3115

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gat...

2025-06-10 21:22 2388

Ambiq Receives Frost & Sullivan's 2025 Global Company of the Year Award for Its Leadership in Healthcare Semiconductor Solutions

Ambiq recognized for pioneering energy-efficient semiconductor solutions that empower next-generation AI-enabled healthcare innovations SAN ANTONIO, June 10, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce thatAmbiq has been awarded the 2025 Global Company of the Year Award in the s...

2025-06-10 21:00 1716

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedT...

2025-06-10 13:45 2324

New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss

Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), first-time hair restoration ...

2025-06-10 09:00 2148

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in...

2025-06-10 09:00 1823

Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health

SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product,MastGut — a pioneering supplement that delivers therapeutic protection directly to the gut. Built on years o...

2025-06-10 08:45 1675

Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care

PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide— Echosens , the leader in non-invasive liver ...

2025-06-10 06:00 2055

Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study

TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, is happy to announce the first U.S. implantations of its atrial-pressure microsensor. Two surgical implantations were performed on Friday, May 16, 2025, at New York-Presbyterian/Columbia University Irv...

2025-06-09 18:00 2134

BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration

China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSee...

2025-06-09 14:51 2925

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association

* EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSG...

2025-06-09 14:16 2384

HIRONIC Successfully Hosts First Asia Innovation Summit 2025

SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th.

2025-06-07 18:21 2588

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 7, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated ...

2025-06-07 11:36 3414

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians. Australia could save $25.2 billion in CKD-related costs and more than...

2025-06-06 23:00 2777

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

* Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early tr...

2025-06-06 16:12 2411

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as  a globalleader in the development and  production of pharmaceut...

2025-06-06 14:00 2299

Kelun-Biotech Announces Approximately US$250 Million Placement

CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of t...

2025-06-06 11:04 4282
1 ... 47484950515253 ... 395

Week's Top Stories